SmartNuclide Biopharmaceutical

Company Deals

Suzhou SmartNuclide Biopharmaceutical Secures $13.8 Million in Series C+ Funding to Advance Radiopharmaceutical Pipeline

Fineline Cube Apr 10, 2024

Suzhou SmartNuclide Biopharmaceutical Co., Ltd, a leading developer of radiopharmaceuticals in China, has announced the...

Company Deals

Smartnuclide Biopharmaceutical Partners with Gosun Pharmaceuticals for rhTSH Market Promotion in China

Fineline Cube Feb 1, 2024

Suzhou Smartnuclide Biopharmaceutical Co., Ltd, a Chinese biopharmaceutical company, has entered into a business cooperation...

Company Deals

Antengene Corporation Secures $980M Global Licensing Deal with K2 Therapeutics for CDH6×CD3 Bispecific T-Cell Engager

Company Deals

CSPC Innovation Pharmaceutical Files Hong Kong IPO Prospectus Following Strategic Evolution from Caffeine Producer to Biopharmaceutical Player

Company Deals

Zhiyi Biotechnology Files Hong Kong IPO Prospectus as China’s Leading Live Biotherapeutic Products Developer

Company Drug

Gan & Lee Pharmaceuticals Secures UAE Approval for Insulin Glargine Prefilled Pen, Expanding Global Diabetes Portfolio